Anti-BTLA Neutralizing Antibody |
100244 |
BPS Bioscience |
100 µg |
EUR 355 |
Description: This anti-BTLA antibody is a purified recombinant human monoclonal antibody which recognizes the human BTLA protein. BTLA (B- and T-lymphocyte attenuator) belongs to the CD28 immunoglobulin superfamily (IgSF) and is an immune-regulatory receptor that binds to HVEM (Herpesvirus entry mediator, also known as TNFRSF14, Tumor necrosis factor receptor superfamily member 14). This antibody has been tested for specific binding to purified human BTLA protein and neutralizes the interaction between BTLA and HVEM. |
Human Antibody Laboratories manufactures the human anti-human neutralizing antibody reagents distributed by Genprice. The Human Anti-Human Neutralizing Antibody reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact human Antibody. Other Human products are available in stock. Specificity: Human Category: Anti-Human Group: Neutralizing Antibody
Anti-CTLA4 (CD152) Neutralizing Antibody |
BPS Bioscience |
100 µg |
EUR 490 |
Description: Neutralizing recombinant human monoclonal antibody recognizing the extracellular domain of CTLA4 and blocking binding of CTLA4 to B7.1 and B7.2. This antibody recognizes human CTLA4 but does not bind to murine CTLA4. This antibody has not been tested for cross-reactivity with other species. |
Anti-β-Amyloid Neutralizing Antibody |
BPS Bioscience |
100 µg |
EUR 465 |
Description: Purified, recombinant, humanized Anti-β-amyloid (IgG1) antibody, expressed in HEK293 cells. This antibody reacts with human β-amyloid and has not been tested for cross-reactivity with other species. |
Anti-IL-17A Neutralizing Antibody |
BPS Bioscience |
100 µg |
EUR 490 |
Description: Neutralizing recombinant human_x000D_chimeric antibody recognizing human IL-17A._x000D_This antibody has not been tested for crossreactivity_x000D_with other species. |
Anti-BCMA Neutralizing Antibody, Mouse IgG1 (recommended for neutralizing assay) |
ACROBIOSYSTEMS |
100ug |
EUR 2354 |
|
Description: Anti-BCMA Neutralizing Antibody, is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with BCMA. |
Human-anti-SARS-CoV-2-antibody(Neutralizing) |
EnoGene |
N/A |
EUR 1777.78 |
Description: N/A |
Anti-PD-L1 (CD274) Neutralizing Antibody |
BPS Bioscience |
100 µg |
EUR 505 |
Description: Neutralizing recombinant chimeric murine/human monoclonal antibody recognizing the extracellular domain of PD-L1 and blocking the binding of PD-L1 to PD-1. This antibody has been shown to cross-react with mouse PD-L1. No other species have been tested. |
Anti-Cetuximab Antibody (AY31) (Non-Neutralizing) |
ACROBIOSYSTEMS |
100ug |
EUR 2354 |
|
Description: Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Cetuximab F(ab')2. |
Neutralizing Antibody information
Anti-CTLA4 (CD152) Neutralizing Antibody |
71212 |
BPS Bioscience |
100 µg |
EUR 490 |
Description: Neutralizing recombinant human monoclonal antibody recognizing the extracellular domain of CTLA4 and blocking binding of CTLA4 to B7.1 and B7.2. This antibody recognizes human CTLA4 but does not bind to murine CTLA4. This antibody has not been tested for cross-reactivity with other species. |
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) |
SAD-S35 |
ACROBIOSYSTEMS |
100ug |
EUR 2974.6 |
|
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) (SAD-S35) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 1.47 μg/mL using SARS-CoV-2 Inhibitor Screening Kit.Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein. |
Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody |
abx411283-02mg |
Abbexa |
0.2 mg |
EUR 678 |
|
Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Human IgG1 (AM180) |
SPD-M180 |
ACROBIOSYSTEMS |
100ug |
EUR 2974.6 |
|
Description: Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Human IgG1 (AM180) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 0.98 μg/mL using SARS-CoV-2 Inhibitor Screening Kit (Cat. No. EP-105).Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein. |
Anti-PD-L1 (CD274) Neutralizing Antibody |
71213 |
BPS Bioscience |
100 µg |
EUR 505 |
Description: Neutralizing recombinant chimeric murine/human monoclonal antibody recognizing the extracellular domain of PD-L1 and blocking the binding of PD-L1 to PD-1. This antibody has been shown to cross-react with mouse PD-L1. No other species have been tested. |
Cytomegalovirus gB Late Neutralizing Antigen (CMV-LA gB Neutralizing) Antibody (FITC) |
abx411284-01mg |
Abbexa |
0.1 mg |
EUR 610.8 |
|
Anti-COVID-19 S-IgM Neutralizing Antibody |
E38A9973 |
EnoGene |
100ug/100ul |
EUR 225 |
Description: Available in various conjugation types. |
Anti-COVID-19 S-IgA Neutralizing Antibody |
E38A9974 |
EnoGene |
100ug/100ul |
EUR 225 |
Description: Available in various conjugation types. |
Anti-COVID-19 S-hIgG1 Neutralizing Antibody |
E38A9970 |
EnoGene |
100ug/100ul |
EUR 225 |
Description: Available in various conjugation types. |
Anti-COVID-19 S-mIgG1 Neutralizing Antibody |
E38A9971 |
EnoGene |
100ug/100ul |
EUR 225 |
Description: Available in various conjugation types. |
Anti-COVID-19 S-cIgG1 Neutralizing Antibody |
E38A9972 |
EnoGene |
100ug/100ul |
EUR 225 |
Description: Available in various conjugation types. |
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) |
S1N-M122 |
ACROBIOSYSTEMS |
100ug |
EUR 2974.6 |
|
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) is a chimeric monoclonal antibody recombinantly expressed from HEK293 cells, which combines the variable region of a mouse monoclonal antibody with human IgG1 constant domain. The mouse monoclonal antibody was obtained from a mouse immunized with recombinant SARS-CoV-2 Spike S1 protein. As verified in competitive ELISA-based and pseudovirus-based neutralization assay, this chimeric monoclonal can potently neutralize all SARS-CoV-2 Variants of Concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529). |
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (AM122) |
SPD-M162 |
ACROBIOSYSTEMS |
100ug |
EUR 2974.6 |
|
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgM (AM122) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). |
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgA1 (AM122) |
SPD-M58P1 |
ACROBIOSYSTEMS |
100ug |
EUR 2974.6 |
|
Description: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgA1 (AM122) is a chimeric monoclonal antibody recombinantly expressed from HEK293 cells, which combines the variable region of a mouse monoclonal antibody with human IgA1 constant domain. The mouse monoclonal antibody was obtained from a mouse immunized with recombinant SARS-CoV-2 Spike S1 protein. |
Interferon alpha Neutralizing Antibody |
20-abx137013 |
Abbexa |
|
|
|
Anti-2019-nCoV S-IgM Neutralizing Antibody (8A5) |
EPT006 |
ELK Biotech |
50ug |
EUR 239.4 |
|
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
Anti-2019-nCoV S-IgA Neutralizing Antibody (8A5) |
EPT018 |
ELK Biotech |
50ug |
EUR 239.4 |
|
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |